Cutaneous Reaction to Drugs Used for Erectile Dysfunction: Case Report and Review of the Literature

Background: In the past 9 years, drugs for erectile dysfunction (ED) have been increasingly prescribed for men with erectile difficulty. These drugs, phosphodiesterase 5 (PDE5) inhibitors, help men with ED obtain and sustain an erection, improving both sexual function and sexual performance satisfaction. However, these drugs contain side effects. Objectives: A 56-year-old man developed an erythematous, circle-shaped lesion on his penis. The lesion was recurrent, with evidence of desquamation. The aim was to determine the source of the recurrent lesion based on its morphology and the patient's verbal history. Results: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made. He was not rechallenged with the drug. However, he experienced a subsequent recurrence of the eruption on inadvertent rechallenge. Conclusions: We believe this case to be the first report of this type of reaction owing to tadalafil. Therefore, fixed drug eruption is a newly observable side effect of this drug.

Download Full-text

Phenanthrenes from Eulophia macrobulbon as Novel Phosphodiesterase-5 Inhibitors

Natural Product Communications ◽

10.1177/1934578x1701200121 ◽

2017 ◽

Vol 12 (1) ◽

pp. 1934578X1701200 ◽

Cited By ~ 1

Author(s):

Prapapan Temkitthawon ◽

Kanokwan Changwichit ◽

Nantaka Khorana ◽

Jarupa Viyoch ◽

Khanit Suwanborirux ◽

...

Keyword(s):

Pulmonary Hypertension ◽

Erectile Dysfunction ◽

Chemical Constituents ◽

Pde5 Inhibitor ◽

Pde5 Inhibitors ◽

New Class ◽

Phosphodiesterase 5 Inhibitors ◽

Phosphodiesterase 5

Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon (E.C. Parish & Rchb. f) Hook. f A new phenanthrene, 9,10-dihydro-4-(4′-hydroxybenzyl)-2,5-dimethoxyphenanthrene-1,7-diol (1) and three known phenanthrenes i.e., 1-(4′-hydroxybenzyl)-4,8-dimethoxyphenanthrene-2,7-diol (2), (9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol (3) and 1,5,7-trimethoxyphenanthrene-2,6-diol) (4) were isolated. Among these, 2 was the most potent PDE5 inhibitor (IC50 =1.67±0.54 μM) evaluated by the [3H]cGMP radioassay method, whereas 1 showed mild activity (IC50 = 62.3±3.3 μM). Their inhibitory selectivities against PDE5 over PDE6 were also studied. This study suggests phenanthrenes as a new class of PDE5 inhibitors.

Download Full-text

Phosphodiesterase 5 Inhibitors for Erectile Dysfunction

Annals of Pharmacotherapy ◽

10.1345/aph.1e487 ◽

2005 ◽

Vol 39 (7-8) ◽

pp. 1286-1295 ◽

Cited By ~ 49

Author(s):

Stephen M Setter ◽

Jason L Iltz ◽

Jack E Fincham ◽

R Keith Campbell ◽

Danial E Baker

Keyword(s):

Clinical Trial ◽

Erectile Dysfunction ◽

Data Extraction ◽

Pde5 Inhibitor ◽

Clinical Trial Data ◽

Research Review ◽

Pde5 Inhibitors ◽

Search Terms ◽

Review Articles ◽

Phosphodiesterase 5

OBJECTIVE To review the pharmacologic and clinical trial data of the Food and Drug Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED). DATA SOURCES Primary research and review articles were identified through a search of ScienceDirect, PubMed/MEDLINE, and International Pharmaceutical Abstracts (1990–August 2004). The following search terms were used in the Medicine Dentistry and Pharmacology, Toxicology, and Pharmaceutical Sciences subcategories: phosphodiesterase 5 inhibitor, PDE5 inhibitor, erectile dysfunction, sildenafil, vardenafil, tadalafil, prostatectomy, and diabetes. Web of Science (1990–August 2004) was used to search for additional abstracts using the same search terms as above. The package inserts for sildenafil, vardenafil, and tadalafil were also consulted. STUDY SELECTION AND DATA EXTRACTION All identified research, review articles, and abstracts were assessed for relevance, and all relevant information was included. Priority was given to the primary medical literature and clinical trial reports. DATA SYNTHESIS ED is a common disorder in males with increased prevalence associated with age and presence of cardiovascular disease, prostatectomy, or diabetes mellitus. Sildenafil, vardenafil, and tadalafil are selective PDE5 inhibitors currently available for treatment of ED. Their pharmacology and pharmacokinetics vary slightly, but with potentially important clinical differences in duration of activity; all have similar clinical efficacy and adverse effect profiles in patients with ED of various causes. CONCLUSIONS Sildenafil, vardenafil, and tadalafil are safe and effective PDE5 inhibitors for the treatment of ED.

Download Full-text

Tylenol or acetaminophen: a recurrent fixed drug eruption perpetuated through the use of inconsistent drug terminology

BMJ Case Reports ◽

10.1136/bcr-2021-241908 ◽

2021 ◽

Vol 14 (8) ◽

pp. e241908

Author(s):

Daniel Federman ◽

Jadry A Gruen ◽

Naseema Merchant

Keyword(s):

Electronic Medical Records ◽

Medical Records ◽

Drug Eruption ◽

Fixed Drug Eruption ◽

Over The Counter ◽

The Past ◽

Fixed Drug ◽

Viral Illness ◽

History Of ◽

Proximal Thigh

An 87-year-old man with a history of osteoarthritis presented with worsening knee pain. He was prescribed acetaminophen with codeine. A few days later, he developed a rash on his right buttock and proximal thigh, similar to a rash he experienced in the past when he took over-the-counter (OTC) acetamenophen and an unknown lozenge to treat a presumed viral illness. A fixed drug eruption (FDE) was diagnosed and the patient was asked to avoid Tylenol and other OTC lozenges. Tylenol was entered as an allergy in the electronic medical records. However, since Tylenol, not acetaminophen was listed in the allergy profile, the order for acetaminophen and codeine did not generate an alert for the prescribing physician. Additionally, the dispensing pharmacist did not question the prescribing physician and the patient, unaware that acetaminophen in the pain medication is the same drug as Tylenol, took it and developed recurrent FDE.

Download Full-text